Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


19.07.2021

2 Br J Cancer
2 Cancer Lett
1 Cancer Res
1 Endocrinology
2 Eur J Radiol
1 Eur Radiol
1 Eur Urol
1 Int J Radiat Oncol Biol Phys
1 J Natl Cancer Inst
7 J Urol
1 Lancet Oncol
1 Oncology (Williston Park)
2 PLoS One
1 Prog Urol
5 Prostate
1 Radiology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Br J Cancer

  1. AHMAD F, Cherukuri MK, Choyke PL
    Metabolic reprogramming in prostate cancer.
    Br J Cancer. 2021 Jul 14. pii: 10.1038/s41416-021-01435.
    PubMed         Abstract available

  2. SUI Y, Hu W, Zhang W, Li D, et al
    Insights into homeobox B9: a propeller for metastasis in dormant prostate cancer progenitor cells.
    Br J Cancer. 2021 Jul 10. pii: 10.1038/s41416-021-01482.
    PubMed         Abstract available


    Cancer Lett

  3. LIANG J, Wang L, Poluben L, Nouri M, et al
    Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells.
    Cancer Lett. 2021 Jul 10. pii: S0304-3835(21)00340.
    PubMed         Abstract available

  4. GAO Y, Liu Y, Liu Y, Peng Y, et al
    UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-Mediated chromatin modifications.
    Cancer Lett. 2021;520:172-183.
    PubMed         Abstract available


    Cancer Res

  5. MAVURA MY, Huang FW
    How Cancer Risk SNPs May Contribute to Prostate Cancer Disparities.
    Cancer Res. 2021;81:3764-3765.
    PubMed         Abstract available


    Endocrinology

  6. MAUVAIS-JARVIS F
    Do Anti-androgens Have Potential as Therapeutics for COVID-19?
    Endocrinology. 2021;162.
    PubMed         Abstract available


    Eur J Radiol

  7. VURAL M, Coskun B, Kilic M, Durmaz S, et al
    In-bore MRI-guided prostate biopsy in a patient group with PI-RADS 4 and 5 targets: A single center experience.
    Eur J Radiol. 2021;141:109785.
    PubMed         Abstract available

  8. CAGLIC I, Sushentsev N, Shah N, Warren AY, et al
    Comparison of biparametric versus multiparametric prostate MRI for the detection of extracapsular extension and seminal vesicle invasion in biopsy naive patients.
    Eur J Radiol. 2021;141:109804.
    PubMed         Abstract available


    Eur Radiol

  9. SUSHENTSEV N, Rundo L, Blyuss O, Nazarenko T, et al
    Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance.
    Eur Radiol. 2021 Jul 13. pii: 10.1007/s00330-021-08151.
    PubMed         Abstract available


    Eur Urol

  10. SUPIOT S, Vaugier L, Pasquier D, Buthaud X, et al
    OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.
    Eur Urol. 2021 Jul 8. pii: S0302-2838(21)01816.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  11. SCHUMACHER O, Luo H, Taaffe DR, Galvao DA, et al
    Effects of exercise during radiotherapy on physical function and treatment-related side effects in men with prostate cancer: a systematic review and meta-analysis.
    Int J Radiat Oncol Biol Phys. 2021 Jul 8. pii: S0360-3016(21)00841.
    PubMed         Abstract available


    J Natl Cancer Inst

  12. KIELY M, Milne GL, Minas TZ, Dorsey TH, et al
    Urinary Thromboxane B2 and Lethal Prostate Cancer in African American Men.
    J Natl Cancer Inst. 2021 Jul 15. pii: 6321959. doi: 10.1093.
    PubMed         Abstract available


    J Urol

  13. FREEDLAND SJ, Howard LE, Ngo A, Ramirez-Torres A, et al
    Low Carbohydrate Diets and Estimated Cardiovascular and Metabolic Syndrome Risk in Prostate Cancer.
    J Urol. 2021 Jul 14:101097JU0000000000002112. doi: 10.1097/JU.0000000000002112.
    PubMed         Abstract available

  14. ROMPRE-BRODEUR A, Marcq G, Tholomier C, Fugaru I, et al
    Role of Systematic Control Biopsies Following Partial Gland Ablation with High-Intensity Focused Ultrasound for Clinically Significant Prostate Cancer.
    J Urol. 2021 Jul 12:101097JU0000000000001934. doi: 10.1097/JU.0000000000001934.
    PubMed         Abstract available

  15. AMIEL T, Wurnschimmel C, Heck M, Horn T, et al
    Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Obs
    J Urol. 2021;205:1663-1670.
    PubMed         Abstract available

  16. DALY WC, Linscott JA, Han PKJ, Hayn MH, et al
    National Recommendations against Prostate Specific Antigen Screening versus Statewide Medicaid Expansion Initiatives: A Battle of the Titans.
    J Urol. 2021;205:1641-1647.
    PubMed         Abstract available

  17. PUNNEN S, Stoyanova R, Kwon D, Reis IM, et al
    Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy.
    J Urol. 2021;205:1344-1351.
    PubMed         Abstract available

  18. MATULEWICZ RS, Basak R, Zambrano I, Dearing BA, et al
    Patterns of Current Cigarette Smoking, Quit Attempts and Cessation Counseling among Survivors of Smoking-Related and Nonsmoking-Related Urological Malignancies: A Nationally Representative Cross-Sectional Analysis.
    J Urol. 2021;205:1444-1451.
    PubMed         Abstract available

  19. PATEL HD, Schwen ZR, Campbell JD, Gorin MA, et al
    Effect of Erythropoietin on Erectile Function after Radical Prostatectomy: The ERECT Randomized Clinical Trial.
    J Urol. 2021;205:1681-1688.
    PubMed         Abstract available


    Lancet Oncol

  20. GAFITA A, Calais J, Grogan TR, Hadaschik B, et al
    Nomograms to predict outcomes after (177)Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.
    Lancet Oncol. 2021 Jul 8. pii: S1470-2045(21)00274.
    PubMed         Abstract available


    Oncology (Williston Park)

  21. MAKEDON A, Maroni P
    Median Lobe Urethral Embolus After Focal Ablation of Gleason 7 Prostate Cancer.
    Oncology (Williston Park). 2021;35:422-424.
    PubMed         Abstract available


    PLoS One

  22. BARRY DELONGCHAMPS N, Schull A, Anract J, Abecassis JP, et al
    Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial.
    PLoS One. 2021;16:e0252040.
    PubMed         Abstract available

  23. ZHANG H, Doucette C, Yang H, Bandyopadhyay S, et al
    Risk of adverse pathological features for intermediate risk prostate cancer: Clinical implications for definitive radiation therapy.
    PLoS One. 2021;16:e0253936.
    PubMed         Abstract available


    Prog Urol

  24. RAVERY V, Adoumadji K, Bras Da Silva C, Vega Toro P, et al
    [MRI of the axial skeleton for evaluation of prostate cancer extent in french Guyana].
    Prog Urol. 2021 Jul 8. pii: S1166-7087(21)00164.
    PubMed         Abstract available


    Prostate

  25. EPSTEIN JI
    Very low-risk versus low-risk prostate cancer: A distinction worth keeping.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24197.
    PubMed        

  26. HUANG D, Ruan X, Wu Y, Lin X, et al
    Genetic polymorphisms at 19q13.33 are associated with [-2]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24192.
    PubMed         Abstract available

  27. LIU G, Zhu Y, Yao Z, Jiang Y, et al
    Development and validation of a predictive model for determining clinically significant prostate cancer in men with negative magnetic resonance imaging after transrectal ultrasound-guided prostate biopsy.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24193.
    PubMed         Abstract available

  28. FETTKE H, Kwan EM, Bukczynska P, Steen JA, et al
    Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24194.
    PubMed         Abstract available

  29. WEI J, Yang W, Shi Z, Lu L, et al
    Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24195.
    PubMed         Abstract available


    Radiology

  30. KANG SK, Mali RD, Prabhu V, Ferket BS, et al
    Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness.
    Radiology. 2021 Jul 13:204321. doi: 10.1148/radiol.2021204321.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: